Roche/Chugai’s Enspryng Not Good Enough In Phase III Myasthenia Gravis Study

Three Phase III Trials Ongoing In Three Other Indications

 
• By Mandy Jackson

Many companies have late-stage myasthenia gravis programs in Phase III, but argenx and its Vyvgart competitors won a reprieve with the failure of IL-6 inhibitor Enspryng (satralizumab).

Concept of Myasthenia Gravis written on sticky notes isolated on Wooden Table.
The myasthenia gravis pharma market is growing despite some setbacks • Source: Shutterstock

More from Clinical Trials

More from R&D